Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Feb 25, 2020 8:08 PM EST

News Releases

Mirum Pharmaceuticals to Participate at Four Upcoming Conferences

February 18, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 18, 2020-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

January 14, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promotion of Ian Clements to Chief Financial

Mirum Pharmaceuticals Announces Pricing of Public Offering

January 8, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares

Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat

December 16, 2019

FDA Requested Change from Type-C Meeting to pre-NDA Meeting Company Plans to Initiate Rolling NDA Submission in Third Quarter 2020 Rare Pediatric Disease Designation Granted for Maralixibat for Alagille Syndrome Conference Call and Webcast today at 8:30 a.m. ET / 5:30 a.m. PT FOSTER CITY, Calif.